Alnylam Maintained at Buy as Strong TTR-Driven Momentum and Pipeline Progress Support Unchanged $510 Price Target

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, retaining the price target of $510.00.

Patrick Trucchio has given his Buy rating due to a combination of factors tied to Alnylam’s strong commercial momentum and outlook. He points to a standout quarter in which revenue surpassed $1 billion, driven largely by exceptional expansion of the TTR franchise, particularly AMVUTTRA’s rapid uptake in ATTR-CM that is nearing Pfizer’s tafamidis in new patient starts, alongside management’s reaffirmed 2026 sales guidance that implies robust double‑digit growth.

In addition, he underscores that Alnylam’s TTR portfolio now contributes the vast majority of product sales, supporting a shift in focus toward scaling margins in line with long‑term targets for revenue growth and non‑GAAP operating profitability by 2030. He also highlights the company’s solid $3.0 billion cash position and the accelerated enrollment and expansion of the TRITON-CM Phase 3 trial for nucresiran, which, together with other RNAi pipeline catalysts, reinforce a durable growth trajectory and support maintaining the unchanged $510 price target.

In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $429.00 price target.

Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.